ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The companies aim to expand treatment options for millions living with metabolic disorders
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
India has taken the lead in recognising NAFLD as a major non-communicable disease
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Subscribe To Our Newsletter & Stay Updated
